Sionna completes Phase 2a SION-719 cystic fibrosis trial enrollment
Sionna posts Q1 2026 non-GAAP EPS -0.60 and completes Phase 2a SION-719 cystic fibrosis trial enrollment
- Fiscal Q1 2026 non-GAAP EPS was -0.60, up 3% YoY, missing analyst EPS estimates.
- Q1 2026 revenue was $0, beating analyst revenue estimates for the quarter.
- An SEC filing detailed a Q1 2026 net loss of $26.8 million for Sionna.
- Quarter-end cash, cash equivalents and marketable securities totaled $289.9 million, projected to fund operations into 2028.
- Phase 1 data for SION-451 are expected to read out this summer.
- Phase 2a data for SION-719 in cystic fibrosis are anticipated this summer.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.